CUE-100 series
Lymphodepletion Enhances MAR-T Cell Therapy Efficacy in Lymphoma Patients, Marker Therapeutics Reports
• Marker Therapeutics' Phase 1 APOLLO study shows lymphodepletion significantly improves expansion and persistence of MT-601 MAR-T cells in lymphoma patients, potentially enhancing anti-tumor activity.
• Early clinical data reveals promising efficacy with 78% objective response rate and 44.4% complete response rate in patients who relapsed after or are not candidates for anti-CD19 CAR-T therapy.
• The non-genetically modified MAR-T cell approach targets six different tumor antigens, demonstrating excellent safety with no dose-limiting toxicities while potentially offering manufacturing advantages over current engineered T cell therapies.
Robust Pipeline of 220+ Drugs Advancing for Gastric Cancer Treatment, Led by Major Pharmaceutical Companies
• DelveInsight's comprehensive analysis reveals over 200 companies actively developing 220+ pipeline therapies for gastric cancer treatment, indicating significant industry investment in addressing this disease.
• Key players including BeiGene, Bristol-Myers Squibb, and AstraZeneca are advancing promising candidates like tislelizumab, relatlimab-nivolumab combination, and trastuzumab deruxtecan through clinical trials.
• Multiple therapeutic approaches are being explored, from monoclonal antibodies to small molecules, with several drugs in late-stage development including Catumaxomab in Phase III and Tivumecirnon in Phase II trials.
Marker Therapeutics Reports Positive Clinical Outcomes for MT-601 in Lymphoma Patients
Marker Therapeutics has provided a clinical update on its Phase 1 APOLLO study of MT-601, showing positive outcomes in patients with lymphoma who have relapsed after CD19 CAR-T cell therapy. The study highlights the potential of MT-601 to address a significant unmet medical need, with observed objective responses in heavily pre-treated patients.
Pancreatic Cancer: Advances in Treatment and Research Bring Hope in 2024
• The five-year relative survival rate for pancreatic cancer has risen to 13%, marking the third consecutive year of improvement, yet it remains the lowest among major solid tumors.
• Four new drug approvals for pancreatic cancer occurred in 2024, including one first-line treatment and three targeted agents for previously treated advanced disease.
• A Phase 3 clinical trial demonstrated an overall survival benefit using Tumor Treating Fields (TTFields) in combination with chemotherapy for unresectable, locally advanced pancreatic cancer.
• Precision medicine is advancing with the FDA approval of Bizengri for NRG1 fusion-positive pancreatic cancer and the ongoing RASolute 302 trial evaluating RMC-6236, a RAS inhibitor.
Cue Biopharma's CUE-101 and CUE-102 Show Promise in Phase 1 Trials for Head and Neck and WT1-Positive Cancers
• CUE-101 combined with pembrolizumab demonstrates a 46% objective response rate and a 91.3% 12-month overall survival rate in first-line HPV+ R/M HNSCC patients.
• In first-line patients with low PD-L1 expression, CUE-101 and pembrolizumab achieved a 50% objective response rate, indicating potential efficacy in challenging cases.
• CUE-102 monotherapy shows a 67% overall disease control rate in late-stage pancreatic cancer, including an unconfirmed partial response with a 40% tumor reduction.
• Both CUE-101 and CUE-102 exhibit favorable tolerability profiles with manageable adverse events, supporting their potential as safe and effective cancer therapies.
Cue Biopharma's CUE-101 and CUE-102 Show Promising Phase 1 Results in Cancer Trials
• Cue Biopharma's CUE-101, combined with pembrolizumab, demonstrated a 46% objective response rate and a 91.3% 12-month overall survival rate in head and neck cancer patients.
• CUE-101 monotherapy showed a median overall survival of 20.8 months in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma patients.
• CUE-102 achieved a 67% disease control rate in late-stage pancreatic cancer patients, including a partial response with a 40% reduction in tumor burden.
• Both CUE-101 and CUE-102 exhibited favorable safety profiles with no significant toxicity concerns in their respective Phase 1 trials.
Cue Biopharma Announces Positive Phase 1 Data for CUE-101 and CUE-102 at SITC 2024
• CUE-101 combined with pembrolizumab shows a 46% objective response rate and 91.3% 12-month overall survival in first-line HPV+ recurrent/metastatic head and neck squamous cell carcinoma patients.
• In first-line patients with low PD-L1 expression, CUE-101 and pembrolizumab achieved a 50% objective response rate, indicating potential efficacy in challenging-to-treat populations.
• CUE-102 monotherapy demonstrates a 67% overall disease control rate in late-stage pancreatic cancer, including an unconfirmed partial response with a 40% tumor burden reduction.
• Both CUE-101 and CUE-102 exhibit favorable tolerability profiles, with no significant safety concerns identified in either monotherapy or combination trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath